Autologous Cell Therapy for Osteoarthritis: An evaluation of the safety and efficacy of autologous transplantation of articular chondrocytes and/or bone marrow-derived stromal cells to repair chondral/osteochondral lesions of the knee. - Autologous Stem Cells, Chondrocytes or the Two? (ASCOT)

RJAH Orthopaedic Hospital0 个研究点目标入组 114 人开始时间: 2011年6月16日最近更新: 2013年5月6日

适应症

试验速览

暂无简介。

•1. A symptomatic chondral defect of the knee that extends to (Outerbridge grade 4) or into the subchondral bone.
•2. The defect is considered suitable for treating with autologous cell therapy.
•3. Previous surgical treatment of the defect has failed to relieve symptoms.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 108
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 6

•1. Positive for HIV, hepatitis B or C, syphilis, or human T cell lymphotrophic virus (HTLV) I or II.
•2. Likely to show contraindications to autologous cell therapy: patients with inflammatory condition, history of mesenchymal tumours, therapy with steroids or methotrexate, bleeding tendency or known anaphylaxis to any product used in cell preparation.
•3. Low probability of compliance with physiotherapy or follow-up, including a major life-threatening condition.

发起方

RJAH Orthopaedic Hospital